In an economy driven by global competition, counterfeits and theft of trade secrets remain major hazards for U.S. drug and device companies, handing them an uneven playing field in some parts of the world. When it comes to counterfeits, most of the problems can be traced to China, which the U.S. Trade Representative's (USTR) 2016 Special 301 Report refers to as "the manufacturing hub of counterfeit products." Together with Hong Kong, India and Singapore, China accounted for 97 percent of all counterfeit drugs seized at the U.S. border last year.